Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956302 · ClinicalTrials.gov registry record · Phase 1
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Abdullah Khan.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04956302: Clinical Trial Phase 1 study, sponsored by Abdullah Khan.
NCT04956302 is a Phase 1 study that was terminated before completion, run by Abdullah Khan. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04956302, a Phase 1 study, was terminated before completion, sponsored by Abdullah Khan.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slow multiple myeloma by blocking the growth of new blood vessels necessary for cancer growth. Giving panobinostat in combination with daratumumab, bortezomib and dexamethasone may work better in treating relapsed/refractory multiple myeloma.
Primary Outcome
A standard "3+3" design will be used to determine the safe and tolerable dose level.
Interventions
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG Daratumumab and Hyaluronidase-fihj
- DRUG Panobinostat Lactate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-09-27 |
| Est. Completion | 2022-06-16 |
| Phase | Phase 1 |
Why NCT04956302 stopped before completion
NCT04956302 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT04956302 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04956302 about?
NCT04956302 is a clinical study titled "Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma". This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slo...
What is the current status of trial NCT04956302?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2021-09-27. Estimated completion is 2022-06-16.
What interventions are being tested in trial NCT04956302?
The interventions under investigation include: Dexamethasone (DRUG), Bortezomib (DRUG), Daratumumab and Hyaluronidase-fihj (DRUG), Panobinostat Lactate (DRUG).
Who is sponsoring clinical trial NCT04956302?
This trial is sponsored by Abdullah Khan, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04956302's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI